Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01593397 · ClinicalTrials.gov registry record · Phase 1
Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT01593397: Completed Phase 1 study, sponsored by Stanford University.
NCT01593397 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01593397, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the influence of insulin resistance on drug metabolism and response in obese subjects. The investigators hypothesize that expression of adiponectin (a hormone secreted by fat tissue), and specific variants in the adiponectin gene can predict the insulin resistance and drug response among obese subjects.
Interventions
- DRUG Propofol and Fentanyl administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2011-11 |
| Est. Completion | 2017-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01593397
The ClinicalTrials.gov registry entry for NCT01593397 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Propofol and Fentanyl administration is the first listed.
NCT01593397 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01593397 about?
NCT01593397 is a clinical study titled "Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity". The primary objective of this study is to determine the influence of insulin resistance on drug metabolism and response in obese subjects. The investigators hypothesize that expression of adiponectin (a hormone secreted by fat tissue), and specific variants in the adiponectin gene can predict the in...
What is the current status of trial NCT01593397?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2011-11. Estimated completion is 2017-09.
What interventions are being tested in trial NCT01593397?
The interventions under investigation include: Propofol and Fentanyl administration (DRUG).
Who is sponsoring clinical trial NCT01593397?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.